Armenicum

Last updated

Armenicum is a drug invented in Armenia in 1998 that its developers claim is an effective treatment for HIV infection and a number of associated diseases. No rigorously monitored clinical trials of Armenicum have been published, and most HIV experts outside of Armenia do not endorse its use. [1]

Contents

Efficacy

In 1999, a BBC investigation involving interviews with scientists involved in administering the drug, patients and creator Alexander Ilyin raised serious doubts about the drug's efficacy, concluding that Armenicum might do more harm than good. Dr. Manfred Dietrich of the Institute for Tropical Medicine in Hamburg told the BBC "I would not recommend at all to take such a drug." while an American patient said "we’re in a worse state than we were before we went." [2]

Ingredients

The main ingredient of Armenicum is iodine, a general antiseptic. According to the manufacturers it also contains dextrin, polyvinyl alcohol, sodium, potassium and lithium cations and chloride anions. It is described as a "blue-violet liquid with specific odor, packed in orange glass bottles per 20ml and corked tightly by a rubber plug clutched by aluminum caps." [3]

Clinical studies

Clinical studies of the drug (1998–2000) were carried out in the Intensive Care Unit of the 1st Infectious Clinical Hospital in Yerevan: head of department, Ph.D. Petr Artishchev (1994–2000). Phase 2A of clinical trials revealed a good tolerance of the drug, a certain direction of adverse events, which constituted an insignificant percentage of the number of observations. Laboratory diagnostics of the tests under study was carried out by the "Prom-Test" Laboratory as a Central laboratory. The head: Arthur Melkonyan. The scientific supervisor from the beginning of the study and until the end of his life was the head of Infectious Diseases department of Yerevan State Medical University, Ph.D. Levon Mkhitaryan (d. 2009). General management was entrusted to Prof. Emil Gabrielyan (d. 2010) – Director of the Republican Pharmacological Agency, who was a Minister of Health of the Armenian SSR in the past.

Company

Later, the formed CJSC “Armenicum” acquired the buildings and the land of the 1st Infectious Clinical Hospital (2000). The reconstructed building was renamed into the “Armenicum Medical Center”, which to this day is engaged in the treatment of HIV infection and works on government orders.

Kolesnikov controversy

On 8 September 2000, Nikolai Kolesnikov, who had received treatment for AIDS in "Armenicum" center in Armenia was reported dead in one of Kaliningrad hospitals. According to his doctors, Armenicum turned out to be a simple immunity modular, without any effect on the virus which continues to damage the cells in the human body. [4]

In March 2005, Kolesnikov was reported to have frozen to death in his native Kaliningrad. There have been several other reports on his death over the years. [5]

Related Research Articles

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

The spread of HIV/AIDS has affected millions of people worldwide; AIDS is considered a pandemic. The World Health Organization (WHO) estimated that in 2016 there were 36.7 million people worldwide living with HIV/AIDS, with 1.8 million new HIV infections per year and 1 million deaths due to AIDS. Misconceptions about HIV and AIDS arise from several different sources, from simple ignorance and misunderstandings about scientific knowledge regarding HIV infections and the cause of AIDS to misinformation propagated by individuals and groups with ideological stances that deny a causative relationship between HIV infection and the development of AIDS. Below is a list and explanations of some common misconceptions and their rebuttals.

The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Immune reconstitution inflammatory syndrome (IRIS) is a condition seen in some cases of HIV/AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.

HIV-associated nephropathy (HIVAN) refers to kidney disease developing in association with infection by human immunodeficiency virus, the virus that causes AIDS. The most common, or "classical", type of HIV-associated nephropathy is a collapsing focal segmental glomerulosclerosis (FSGS), though other forms of kidney disease may also occur. Regardless of the underlying histology, kidney disease in HIV-positive patients is associated with an increased risk of death.

Douglas D. Richman is an American infectious diseases physician and medical virologist. Richman's work has focused on the HIV/AIDS pandemic, since its appearance in the early 1980s. His major contributions have been in the areas of treatment, drug resistance, and pathogenicity.

<span class="mw-page-title-main">Extensively drug-resistant tuberculosis</span> Tuberculosis that is resistant to the most effective drugs

Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).

<span class="mw-page-title-main">HIV/AIDS in Russia</span> Situation around HIV/AIDS in Russia

The situation with the spread of HIV/AIDS in Russia is described by some researchers as an epidemic. The first cases of human immunodeficiency virus infection were recorded in the USSR in 1985-1987. Patient zero is officially considered to be a military interpreter who worked in Tanzania in the early 1980s and was infected by a local man during sexual contact. After 1988—1989 Elista HIV outbreak, the disease became known to the general public and the first AIDS centers were established. In 1995-1996, the virus spread among injecting drug users (IDUs) and soon expanded throughout the country. By 2006, HIV had spread beyond the vulnerable IDU group, endangering their heterosexual partners and potentially the entire population.

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated.

<span class="mw-page-title-main">Fairfield Infectious Diseases Hospital</span> Hospital in Fairfield, Australia

Fairfield Infectious Diseases Hospital, originally known as Queens Memorial Infectious Diseases Hospital, operated from 1904 to its closure in 1996. Perched high on the banks of the Yarra River at Yarra Bend in the inner Melbourne suburb of Fairfield, it developed an international reputation for the research and treatment of infectious diseases. When it closed, it was the last specific infectious diseases hospital in Australia.

<span class="mw-page-title-main">Vaccine Research Center</span>

The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

Anita Rachlis, M.D. is a Canadian HIV/AIDS researcher and is the principal author of the HIV treatment guidelines in Canada. She is an associate scientist at the Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, in Toronto, Ontario, Canada.

<span class="mw-page-title-main">Signs and symptoms of HIV/AIDS</span>

The stages of HIV infection are acute infection, latency, and AIDS. Acute infection lasts for several weeks and may include symptoms such as fever, swollen lymph nodes, inflammation of the throat, rash, muscle pain, malaise, and mouth and esophageal sores. The latency stage involves few or no symptoms and can last anywhere from two weeks to twenty years or more, depending on the individual. AIDS, the final stage of HIV infection, is defined by low CD4+ T cell counts, various opportunistic infections, cancers, and other conditions.

<span class="mw-page-title-main">HIV/AIDS research</span> Field of immunology research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

Julio S. G. Montaner, is an Argentine-Canadian physician, professor and researcher. He is the director of the British Columbia Centre for Excellence in HIV/AIDS, the chair in AIDS Research and head of the Division of AIDS in the Faculty of Medicine at the University of British Columbia and the past-president of the International AIDS Society. He is also the director of the John Ruedy Immunodeficiency Clinic, and the Physician Program Director for HIV/AIDS PHC. He is known for his work on HAART, a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial.

Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.

Michael Seth Silverman is a Canadian specialist in HIV/AIDS and infectious disease and Chief of Infectious Diseases at Saint Joseph’s Health Centre and London Health Sciences Centre, at the University of Western Ontario, in London, Ontario, Canada.

Professor Ravindra "Ravi" Kumar Gupta is a professor of clinical microbiology at the Cambridge Institute of Therapeutic Immunology and Infectious Disease at the University of Cambridge. He is also a member of the faculty of the Africa Health Research Institute in Durban, South Africa.

<span class="mw-page-title-main">Robert T. Schooley</span> American infectious disease physician

Robert "Chip" T. Schooley is an American infectious disease physician, who is the Vice Chair of Academic Affairs, Senior Director of International Initiatives, and Co-Director at the Center for Innovative Phage Applications and Therapeutics (IPATH), at the University of California San Diego School of Medicine. He is an expert in HIV and hepatitis C (HCV) infection and treatment, and in 2016, was the first physician to treat a patient in the United States with intravenous bacteriophage therapy for a systemic bacterial infection.

<span class="mw-page-title-main">Charles Flexner</span> American physician and pharmaceutical scientist

Charles Williams Flexner is an American physician, clinical pharmaceutical scientist, academic, author and researcher. He is a Professor of Medicine at the Johns Hopkins University School of Medicine.

References

  1. ↑ "Scepticism over Aids 'cure'". BBC News. Retrieved 2017-06-21.
  2. ↑ "Access Armenicum". BBC World Service. 20 July 2000. Retrieved 2017-06-21.
  3. ↑ ARMENICUM is a highly promising drug for treatment of HIV infection and AIDS Archived December 5, 2008, at the Wayback Machine
  4. ↑ Patient Treated With Armenicum Dies. Asbarez.com, September 8, 2000
  5. ↑ Nikolay Kolesnikov Dead Having Reportedly Frozen To Death. Public Radio of Armenia, March 19, 2005 Archived May 31, 2011, at the Wayback Machine

Sources

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.